Therefore, targeted delivery systems - such as nano-polymeric carriers, which have shown efficacy in preclinical breast cancer studies[61] - may offer a promising approach to enhance tumor-selective uptake of RCC1 inhibitors and chemotherapeutics while minimizing adverse effects. Here, RCC1 is linked to breast carcinoma.